Research graph
References from Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol. Local targets link to admitted publications; unresolved targets remain external evidence.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2024.0007 · 2024 · External reference
Management of Myeloproliferative Neoplasms (MPNs)
10.1177/10781552221082293 · 2022 · External reference
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · 2022 · External reference
Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia
10.3390/cancers13040798 · 2021 · External reference
Unresolved reference
External reference
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2022.0046 · 2022 · External reference
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
10.1038/s41375-020-0776-2 · 2020 · External reference
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
10.1080/10428194.2021.1969388 · 2022 · External reference
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
10.1002/ajh.25792 · 2020 · External reference
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
10.1186/1756-8722-3-47 · 2010 · External reference
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
10.1200/jco.2009.26.3087 · 2010 · External reference
Unresolved reference
2003 · External reference
Patient medication adherence: measures in daily practice
10.5001/omj.2011.38 · 2011 · External reference
Unresolved reference
External reference
Mapping modifiable determinants of medication adherence in bipolar disorder (BD) to the theoretical domains framework (TDF): a systematic review
10.1017/s0033291721001446 · 2021 · External reference
Interventions for helping patients to follow prescriptions for medications
10.1002/14651858.cd000011 · 2002 · External reference
Medication adherence and intervention strategies: why should we care
10.1007/s44411-025-00227-0 · 2025 · External reference
Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework
10.1111/opo.13245 · 2024 · External reference
A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems
10.1186/s13012-017-0605-9 · 2017 · External reference
Validation of the theoretical domains framework for use in behaviour change and implementation research
10.1186/1748-5908-7-37 · 2012 · External reference
From Theory to Intervention: Mapping Theoretically Derived Behavioural Determinants to Behaviour Change Techniques
10.1111/j.1464-0597.2008.00341.x · 2008 · External reference
A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas
10.26633/rpsp.2022.112 · 2022 · External reference
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
10.1186/2046-4053-4-1 · 2015 · External reference
Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ
10.1186/1471-2288-12-181 · 2012 · External reference
Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis
10.1002/jha2.954 · 2024 · External reference
Unresolved reference
2025 · External reference
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
2002 · External reference
Unresolved reference
External reference
Rayyan-a web and mobile app for systematic reviews
10.1186/s13643-016-0384-4 · 2016 · External reference
An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers
10.2307/2529786 · 1977 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · External reference
The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies
10.11124/jbies-24-00103 · 2025 · External reference
Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better
10.1186/s40779-020-00238-8 · 2020 · External reference
Unresolved reference
External reference
Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study
10.1016/j.jclinepi.2019.03.008 · 2019 · External reference
Grading quality of evidence and strength of recommendations
10.1136/bmj.328.7454.1490 · 2004 · External reference
Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual)
10.1371/journal.pmed.1001895 · 2015 · External reference
Interventions for helping patients to follow prescriptions for medications
10.1002/14651858.cd000011 · ExternalCitation · doi-reference
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
10.1002/ajh.25792 · ExternalCitation · doi-reference
Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis
10.1002/jha2.954 · ExternalCitation · doi-reference
Medication adherence and intervention strategies: why should we care
10.1007/s44411-025-00227-0 · ExternalCitation · doi-reference
Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study
10.1016/j.jclinepi.2019.03.008 · ExternalCitation · doi-reference
Mapping modifiable determinants of medication adherence in bipolar disorder (BD) to the theoretical domains framework (TDF): a systematic review
10.1017/s0033291721001446 · ExternalCitation · doi-reference
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
10.1038/s41375-020-0776-2 · ExternalCitation · doi-reference
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
10.1080/10428194.2021.1969388 · ExternalCitation · doi-reference
From Theory to Intervention: Mapping Theoretically Derived Behavioural Determinants to Behaviour Change Techniques
10.1111/j.1464-0597.2008.00341.x · ExternalCitation · doi-reference
Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework
10.1111/opo.13245 · ExternalCitation · doi-reference
The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies
10.11124/jbies-24-00103 · ExternalCitation · doi-reference
Grading quality of evidence and strength of recommendations
10.1136/bmj.328.7454.1490 · ExternalCitation · doi-reference
Management of Myeloproliferative Neoplasms (MPNs)
10.1177/10781552221082293 · ExternalCitation · doi-reference
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · ExternalCitation · doi-reference
Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ
10.1186/1471-2288-12-181 · ExternalCitation · doi-reference
Validation of the theoretical domains framework for use in behaviour change and implementation research
10.1186/1748-5908-7-37 · ExternalCitation · doi-reference
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
10.1186/1756-8722-3-47 · ExternalCitation · doi-reference
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
10.1186/2046-4053-4-1 · ExternalCitation · doi-reference
A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems
10.1186/s13012-017-0605-9 · ExternalCitation · doi-reference
Rayyan-a web and mobile app for systematic reviews
10.1186/s13643-016-0384-4 · ExternalCitation · doi-reference
Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better
10.1186/s40779-020-00238-8 · ExternalCitation · doi-reference
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
10.1200/jco.2009.26.3087 · ExternalCitation · doi-reference
Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual)
10.1371/journal.pmed.1001895 · ExternalCitation · doi-reference
An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers
10.2307/2529786 · ExternalCitation · doi-reference
A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas
10.26633/rpsp.2022.112 · ExternalCitation · doi-reference
Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia
10.3390/cancers13040798 · ExternalCitation · doi-reference
Patient medication adherence: measures in daily practice
10.5001/omj.2011.38 · ExternalCitation · doi-reference
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2022.0046 · ExternalCitation · doi-reference
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2024.0007 · ExternalCitation · doi-reference
